CureDuchenne congratulates the incredible Dyne Therapeutics team, who recently announced closing $115M in equity financing to develop transformational therapies for patients with serious muscle diseases. We share this news in celebration with everyone in the greater muscle disease space along with the Duchenne community.
CureDuchenne Venture’s expertise and investment played an important role in accelerating Duchenne as a disease target in Dyne’s drug development pipeline. The goal of CureDuchenne Ventures is to grow the Duchenne therapeutic research pipeline using our philanthropic investment dollars, just as we did with Dyne. We applaud their successful $115M Series B raise and welcome the top tier investors who, alongside CureDuchenne’s Series A investment, will transform the Duchenne therapy space by accelerating this promising program.
This $115M in capital will enable Dyne to further a pipeline of modern oligonucleotide therapeuticsusing their FORCE™ platform, which is aimed at transforming the lives of individuals living with serious muscle diseases. It accelerates the development of Dyne’s pipeline of muscle disease therapies, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD), as well as additional indications, including cardiac and metabolic muscle diseases.
CureDuchenne Ventures strategically applies our expertise and business acumen year over year in the effort to achieve our goal of funding transformational therapies. Dyne’s recent capital infusion proves that our involvement and critical assessments of forward-thinking projects helps accelerate Duchenne drug discovery for all impacted by this disease.
We look forward to seeing great things from Dyne in the future and once again congratulate them on their bright new horizon. Together, we can and WILL cure Duchenne!